SAN DIEGO , Oct. 6, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21 st International Congress of the World Muscle Society in Granada, Spain .

SAN DIEGO , Sept. 29, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced participation in the upcoming 21 st International Annual

SAN DIEGO , Sept. 21, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that David J. King , PhD, has joined the company as Senior Vice President, Research. Dr. King will lead aTyr's research and preclinical efforts to advance its Physiocrine biology and support the clinical

- On Track to Announce Data from Three Clinical Trials for Resolaris™ in Rare Genetic Muscle Diseases in 4Q16 - - 2nd Potential First in Class Molecule iMod.Fc, On Track to Enter Clinic in 2017 - - Maintains Strong Cash Position: $96.6 Million at End of 2Q16 -   SAN DIEGO , Aug.

SAN DIEGO , June 3, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the Jefferies 2016 Healthcare Conference

Company Continues Development Strategy Leveraging Resokine Pathway   SAN DIEGO , May 11, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today

SAN DIEGO , May 5, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that Grove Matsuoka, has joined the company as Senior Vice President,

SAN DIEGO , April 29, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation in two upcoming investor conferences.

SAN DIEGO , April 6, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the 15th Annual Needham & Company

Company Continues Expansion of Resolaris™ Program   SAN DIEGO , March 30, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced